| Date Filed | Type | Description |
| 04/21/2021 |
GN
| Royalty Pharma to Announce First-Quarter 2021 Financial Results on May 11, 2021 |
| 04/21/2021 |
GN
| Royalty Pharma Announces Strategic Alliance With MSCI to Launch Life Sciences Indexes |
| 04/15/2021 |
GN
| Royalty Pharma Declares Second-Quarter 2021 Dividend |
| 04/08/2021 |
GN
| Royalty Pharma Acquires OXLUMO™ Royalty Interest From Dicerna for up to $240 Million |
| 02/17/2021 |
GN
| Royalty Pharma Reports Q4 2020 and Full-Year Results |
| 01/22/2021 |
GN
| Royalty Pharma to Announce Fourth-Quarter 2020 Financial Results on February 17, 2021 |
| 01/08/2021 |
GN
| Royalty Pharma Announces 13% Dividend Increase |
| 12/22/2020 |
GN
| Royalty Pharma Announces Charitable Gifts to Support COVID-19 Research at Leading Hospitals and Universities |
| 12/21/2020 |
GN
| Royalty Pharma Announces Expansion of Leadership Team |
| 12/07/2020 |
GN
| Royalty Pharma Acquires Royalty Interest in ORLADEYO and BCX9930 From BioCryst Pharmaceuticals |
| 12/07/2020 |
GN
| BioCryst Announces $325 Million of Funding from Royalty Pharma and Athyrium Capital Management |
| 11/10/2020 |
GN
| Royalty Pharma Reports Third Quarter 2020 Results |
| 11/02/2020 |
GN
| Royalty Pharma Acquires Additional Royalty Interest From the Cystic Fibrosis Foundation |
| 10/20/2020 |
GN
| Royalty Pharma Announces Closing of Secondary Offering of Class A Ordinary Shares by Selling Shareholders |
| 10/15/2020 |
GN
| Royalty Pharma Announces Pricing of Secondary Offering of Class A Ordinary Shares by Selling Shareholders |
| 10/15/2020 |
GN
| Royalty Pharma Declares Fourth-Quarter 2020 Dividend |
| 10/13/2020 |
GN
| Royalty Pharma Announces Secondary Offering of Class A Ordinary Shares by Selling Shareholders |
| 09/02/2020 |
GN
| Royalty Pharma Announces Closing of $6.0 Billion Senior Unsecured Notes |
| 08/25/2020 |
GN
| Royalty Pharma Announces Pricing of $6.0 Billion Senior Unsecured Notes |
| 08/12/2020 |
GN
| Royalty Pharma Reports Second Quarter 2020 Results |
| 08/07/2020 |
GN
| Biohaven and Royalty Pharma Announce Funding Agreement Totaling up to $450 Million |
| 08/03/2020 |
GN
| Royalty Pharma Appoints Henry A. Fernandez and Ted W. Love, M.D. to the Company's Board of Directors |
| 07/20/2020 |
GN
| Royalty Pharma to Announce Second-Quarter 2020 Financial Results on August 12 |
| 07/20/2020 |
GN
| Royalty Pharma Acquires Royalty Interest in Risdiplam From PTC Therapeutics |
| 06/18/2020 |
GN
| Royalty Pharma Announces Closing of Initial Public Offering |
| 02/14/2019 |
SC 13G/A
| Rosalind Advisors, Inc. reports a 0% stake in Repros Therapeutics Inc. |
| 02/13/2018 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/09/2018 |
15-12B
| Form 15-12B - Securities registration termination [Section 12(b)]: |
| 02/07/2018 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 02/07/2018 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 02/07/2018 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 02/07/2018 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 02/07/2018 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 01/31/2018 |
4
| Wyllie Michael (Director) has filed a Form 4 on REPROS THERAPEUTICS INC.|
Txns:
| Unknown transaction of 21,580 shares
@ $0.67, valued at
$14.5k
Disposed/sold 27,779 shares
@ $0.67, valued at
$18.6k
Disposed/sold 5,000 options
@ $0.32, valued at
$1.6k
|
|
|